We serve Chemical Name:4-Bromo-2-nitro-5-(trifluoromethyl)aniline CAS:683241-86-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Bromo-2-nitro-5-(trifluoromethyl)aniline
CAS.NO:683241-86-3
Synonyms:4-bromo-2-nitro-5-trifluoromethyl-phenylamine;5-Amino-2-bromo-4-nitrobenzotrifluoride
Molecular Formula:C7H4BrF3N2O2
Molecular Weight:285.01800
HS Code:2921420090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:71.84000
Exact Mass:283.94100
LogP:4.06270
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-bromo-2-nitro-5-trifluoromethyl-phenylamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Amino-2-bromo-4-nitrobenzotrifluoride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Amino-2-bromo-4-nitrobenzotrifluoride Use and application,4-bromo-2-nitro-5-trifluoromethyl-phenylamine technical grade,usp/ep/jp grade.
Related News: SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 10-hydroxy-11-(1-hydroxy-2,4-dimethyl-hepta-2,5-dienyl)-16-methoxy-18-(4-methoxy-benzyloxy)-9,17,19,21,23-pentamethyl-20-triisopropylsilanyloxy-15-(2-trimethylsilanyl-ethoxymethoxy)-13-oxa-1,5-dithia-spiro[5.17]tricos-21-en-14-one manufacturers He joins us at a pivotal time as our Jinkō® platform goes from strength to strength as we expand our portfolio of partnerships. Grégoire’s strategic and operational expertise will be a vital part of our future success in accelerating and de-risking clinical trials. (37-Hydroxymethyl-2,5,8,11,14,19,22,25,28,31-decaoxa-tricyclo[30.2.2.215,18]octatriaconta-1(35),15(38),16,18(37),32(36),33-hexaen-16-yl)-methanol suppliers A number of drugmakers are also developing inhaled treatments for COVID-19, including Verona Pharma. 1,3-ditert-butyl-2,2,4,4-tetramethyl-1,3,2,4-diazasilastannetidine vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 10-hydroxy-11-(1-hydroxy-2,4-dimethyl-hepta-2,5-dienyl)-16-methoxy-18-(4-methoxy-benzyloxy)-9,17,19,21,23-pentamethyl-20-triisopropylsilanyloxy-15-(2-trimethylsilanyl-ethoxymethoxy)-13-oxa-1,5-dithia-spiro[5.17]tricos-21-en-14-one manufacturers He joins us at a pivotal time as our Jinkō® platform goes from strength to strength as we expand our portfolio of partnerships. Grégoire’s strategic and operational expertise will be a vital part of our future success in accelerating and de-risking clinical trials. (37-Hydroxymethyl-2,5,8,11,14,19,22,25,28,31-decaoxa-tricyclo[30.2.2.215,18]octatriaconta-1(35),15(38),16,18(37),32(36),33-hexaen-16-yl)-methanol suppliers A number of drugmakers are also developing inhaled treatments for COVID-19, including Verona Pharma. 1,3-ditert-butyl-2,2,4,4-tetramethyl-1,3,2,4-diazasilastannetidine vendor & factory.
